Real-world experience of hetrombopag in immune thrombocytopenia treatment: a retrospective cohort study
Hetrombopag was effective and safe in the real-world treatment of ITP. An initial dosage of hetrombopag 5 mg/d and a higher megakaryocyte count in bone marrow may predict better therapeutic efficacy.
Authors
- Cheng Chang (ORCID: https://orcid.org/0000-0002-0361-2438)
- Yimei Feng (ORCID: https://orcid.org/0000-0003-1904-791X)
- Xi Zhang (ORCID: https://orcid.org/0000-0002-8548-2832)
- Quan Yao
- Zhongmin Zou
- Dan Wang (ORCID: https://orcid.org/0009-0009-8060-9054)
Institutions
- Army Medical University (CN)
- Chengdu Military General Hospital (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1186/s40001-025-02850-7
- Citations
- 1
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Regeneron Pharmaceuticals
- National Natural Science Foundation of China
- Army Medical University
- Centre Scientifique et Technique du Bâtiment
- National Health Commission of the People's Republic of China